Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362471 | 0.85 | ALDH1A1 (0.48) | ALDH1A1GAASMN1; SMN2PTGDR2SNCA | |
| SCHEMBL8193976 | 0.77 | CA2 (0.59) | ALDH1A1GAASMN1; SMN2HTTCA2 | |
| SCHEMBL5363756 | 0.73 | LMNA (0.62) | ALDH1A1SMN1; SMN2HTTCA9CA12 | |
| SCHEMBL23143830 | 0.73 | PTGDR2 (0.47) | ALDH1A1PTGDR2KDM4EHTTKMT2A | |
| SCHEMBL20915127 | 0.73 | TDP1 (0.62) | GAASMN1; SMN2PTGDR2HTTCA2 | |
| SCHEMBL5362778 | 0.72 | HTT (0.71) | ALDH1A1GAASMN1; SMN2KDM4EHTT | |
| SCHEMBL1129234 | 0.71 | KDM4E (0.56) | GAASMN1; SMN2KDM4EHTTCA2 | |
| SCHEMBL3901499 | 0.71 | CASP6 (0.46) | ALDH1A1PTGDR2KDM4EHTTMEN1 | |
| SCHEMBL2007287 | 0.71 | POLB (0.70) | GAASMN1; SMN2HTTCA2CA1 | |
| SCHEMBL5366352 | 0.70 | PTGDR2 (0.50) | ALDH1A1SMN1; SMN2PTGDR2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1644352-A1 | PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS | Allergan, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016917-A1 | PROCESS FOR PREPARING ISOMERICALLY PURE PRODRUGS OF PROTON PUMP INHIBITORS | ALLERGAN, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | ALDH1A1 1650/4885GAA 134/4885SMN1; SMN2 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.